Obinil-HS Capsule contains Orlistat 60 mg, a potent lipase inhibitor indicated for the management of obesity. It acts by selectively inhibiting gastric and pancreatic lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of dietary fat, Orlistat facilitates weight reduction and helps maintain weight loss when used in conjunction with a reduced-calorie diet and lifestyle modifications. Obinil-HS is recommended for adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² in the presence of other risk factors such as hypertension, diabetes mellitus, or dyslipidemia. Clinical studies have demonstrated its efficacy in promoting significant weight loss, improving cardiovascular risk factors, and enhancing glycemic control in obese patients. The capsule should be administered orally with meals containing fat, typically three times daily. Common adverse effects include gastrointestinal disturbances such as oily spotting, flatulence with discharge, fecal urgency, and increased defecation, which are generally mild and related to unabsorbed fat. Patients should adhere to a nutritionally balanced, reduced-fat diet to minimize side effects and ensure adequate intake of fat-soluble vitamins. Obinil-HS is contraindicated in pregnancy, chronic malabsorption syndromes, and cholestasis. Regular monitoring and counseling are essential to optimize therapeutic outcomes.